[1]王宇鹏,杜学明.上腔静脉压迫综合征的放化疗治疗[J].医学信息,2022,35(21):163-166.[doi:10.3969/j.issn.1006-1959.2022.21.044]
　WANG Yu-peng,DU Xue-ming.Chemoradiotherapy for Superior Vena Cava Compression Syndrome[J].Journal of Medical Information,2022,35(21):163-166.[doi:10.3969/j.issn.1006-1959.2022.21.044]
点击复制

上腔静脉压迫综合征的放化疗治疗()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年21期
页码:
163-166
栏目:
综述
出版日期:
2022-11-01

文章信息/Info

Title:
Chemoradiotherapy for Superior Vena Cava Compression Syndrome
文章编号:
1006-1959（2022）21-0163-04
作者:
王宇鹏; 杜学明
（天津市北辰医院肿瘤科，天津 300400）
Author(s):
WANG Yu-peng; DU Xue-ming
(Department of Oncology,Beichen Hospital,Tianjin 300400,China)
关键词:
上腔静脉压迫综合征; 肿瘤; 放化疗
Keywords:
Superior vena cava syndrome; Tumor; Chemoradiotherapy
分类号:
R730.53
DOI:
10.3969/j.issn.1006-1959.2022.21.044
文献标志码:
A
摘要:
上腔静脉综合征是肿瘤常见的并发症，是由流经上腔静脉的血流受阻而导致的一组综合征。临床患者伴有呼吸困难、面颈部水肿、躯干上肢水肿，部分患者还伴有胸痛、咳嗽、吞咽困难等症状，严重影响患者的生活质量和健康安全。上腔静脉压迫综合征属于肿瘤急症或亚急症范畴，其发生与上腔静脉受胸内肿瘤压迫相关。有研究显示大部分诱病肿瘤均属于放疗、化疗敏感的肿瘤，而放疗、化疗具有局部控制效果好、耐受性好、周边健康组织损伤小、无创伤等优点，是目前临床治疗上腔静脉压迫综合征的首选治疗方法。本文就上腔静脉压迫综合征病因、临床症状、放化疗治疗进展作一综述，以期为临床采用放化疗治疗上腔静脉压迫综合征提供一定参考依据。
Abstract:
Superior vena cava syndrome is a common complication of tumors. It is a group of syndromes caused by obstruction of blood flow through the superior vena cava. Patients are accompanied by dyspnea, facial and neck edema, trunk and upper limb edema, and some patients are accompanied by chest pain, cough, dysphagia and other symptoms, which seriously affect the quality of life and health and safety of patients. Superior vena cava compression syndrome belongs to the category of tumor emergency or subacute, and its occurrence is related to superior vena cava compression by intrathoracic tumor. Studies have shown that most of the induced tumors are sensitive to radiotherapy and chemotherapy. Radiotherapy and chemotherapy have the advantages of good local control effect, good tolerance, small damage to surrounding healthy tissues, and non-invasiveness. It is the preferred treatment for superior vena cava compression syndrome. This article reviews the etiology, clinical symptoms, radiotherapy and chemotherapy treatment progress of superior vena cava compression syndrome, in order to provide a reference for the clinical use of radiotherapy and chemotherapy in the treatment of superior vena cava compression syndrome.

参考文献/References:

[1]陈佳权,崔玉梅.68例上腔静脉压迫综合征放化疗疗效分析[J].现代肿瘤医学,2016,24(3):463-465.[2]吴清木,张江灵,郑维斌,等.体部伽玛刀联合化疗姑息治疗癌性上腔静脉综合征的临床观察[J].临床肿瘤学杂志,2017,22(5):450-454.[3]崔继承,丁长青,曹远东,等.多层螺旋CT在肺癌致上腔静脉综合征中的应用价值[J].肿瘤基础与临床,2016,29(3):231-232,233.[4]Urushiyama H,Jo T,Yasunaga H,et al.Adjuvant chemotherapy versus chemoradiotherapy for small cell lung cancer with lymph node metastasis:a retrospective observational study with use of a national database in Japan[J].BMC Cancer,2017,17(1):613.[5]Liu X,Zhang S,Li J.Progress on the Therapeutic Approaches for Malignant Tumor with Superior Vena Cava Syndrome[J].Chinese Journal of Lung Cancer,2016,19(11):784-788.[6]金昌,吴常生,赵蒙,等.支架植入联合支气管动脉栓塞化疗治疗肺癌致上腔静脉综合征的临床疗效[J].中华介入放射学电子杂志,2017,5(2):94-97.[7]王磊,李灵招,单国用,等.伽玛刀联合超声刀治疗局部中晚期肝癌临床研究[J].中华实用诊断与治疗杂志,2018,32(12):1209-1212.[8]马骖,谭遥,樊一萌,等.IMRT与VMAT治疗小细胞肺癌合并上腔静脉压迫综合征患者的急性不良反应比较[J].癌症进展,2019,17(7):804-807.[9]Madkaiker AN,Krishna N,Jose R,et al.Superior Vena Cava Syndrome Caused by Pacemaker Leads[J]. Ann Thorac Surg,2016,101(6):2358-2361.[10]张爱灵,王维.常规分割与大分割三维适形放射治疗非小细胞肺癌合并上腔静脉压迫综合征[J].昆明医科大学学报,2016,37(6):77-81.[11]赵航.同步放化疗及序贯放化疗在小细胞肺癌合并上腔静脉压迫综合征中的效果观察[J].实用医学影像杂志,2020,21(2):203-205.[12]Zimmerman S,Davis M.Rapid Fire: Superior Vena Cava Syndrome[J].Emerg Med Clin North Am,2018,36(3):577-584.[13]蔡丽华,常娟,肖扬,等.伴隐匿上腔静脉综合征胸腔肿瘤患者行上肢PICC置管化疗的安全性研究[J].中国肿瘤外科杂志,2017,9(6):408-410.[14]Ciammella P,Timon G,Bruni A,et al.Radiation therapy in small cell lung cancer: a national Italian survey[J].Radiol Med,2018,123(7):554-560.[15]郭燕,马骖,刘朝兴,等.同步放化疗及序贯放化疗在小细胞肺癌合并上腔静脉压迫综合征中的效果研究[J].临床误诊误治,2019,32(10):90-94.[16]杨李思瑞,田菲,王夏妮,等.125I粒子植入联合扶正合剂治疗非小细胞肺癌相关上腔静脉综合征临床疗效分析[J].中华中医药杂志,2020,35(6):3187-3190.[17]Sakurai M,Tsurukiri J.Superior Vena Cava Syndrome with Cardiac Device-related Infective Endocarditis Secondary to Pacemaker Infection[J].J Emerg Med,2016,50(5):e237-e238.[18]肖颖,刘永亮,王海波,等.后程三维适形放疗联合吉非替尼治疗老年非小细胞肺癌伴脑转移癌的疗效[J].中国老年学杂志,2011,31(10):1767-1768.[19]葛方红,谢国栋,顾红芳,等.综合疗法治疗肺癌合并上腔静脉综合征19例临床观察[J].浙江临床医学,2015,17(1):57-58.[20]徐鹏飞,李孟,黄辉.46例肺癌合并上腔静脉综合征的临床分析[J].现代肿瘤医学,2015(11):1528-1530.[21]李芳娟,孙希文,梁世雄,等.血管内支架治疗非小细胞肺癌合并上腔静脉综合征的疗效[J].中华肿瘤杂志,2015,37(1):47-51.[22]Huang CC,Hsu HL,Teng CJ,et al.An Unusual Cause of Superior Vena Cava Syndrome: Loculated Malignant Pericardial Effusion[J].J Thorac Oncol,2016,11(5):774-775.[23]王宇鹏,胡永进,韩玲,等.125I粒子植入联合动脉灌注化疗治疗肺癌所致上腔静脉综合征的近期疗效观察[J].现代诊断与治疗,2020,31(22):3599-3601.[24]Lim KE,Shen TC.Surgical Treatment of an Invasive Thymoma with Intracaval and Intracardiac Extension[J].Acta Cardiol Sin,2017,33(2):204-206.[25]陈育标.TP方案诱导化疗联合三维适形放疗同期化疗治疗非小细胞肺癌的临床研究[J].临床和实验医学杂志,2016,15(12):1161-1163.[26]Damhuis R,Widder J,Senan S.Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands[J].Clin Oncol (R Coll Radiol),2018,30(1):17-22.[27]于广娟.急诊放化疗救治恶性肿瘤合并上腔静脉综合征的疗效分析[J].基层医学论坛,2016(6):751-752.[28]周云洪,闵凤英,薛芬,等.局部晚期鼻咽癌同期调强放化疗的黏膜炎和静脉炎[J].复旦学报(医学版),2020,47(5):795-798.

相似文献/References:

[1]杨森果,毛大华,杨海松,等.E-cadherin与肿瘤侵袭、转移相关性研究进展[J].医学信息,2018,31(03):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
　YANG Sen-guo,MAO Da-hua,YANG Hai-song,et al.Research Progress of the Correlation between E-cadherin and Tumor Invasion and Metastasis[J].Journal of Medical Information,2018,31(21):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
[2]江立基,李先明.碳酸酐酶Ⅸ在肿瘤中的研究进展[J].医学信息,2018,31(03):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
　JIANG Li-ji,LI Xian-ming.Research Progress of Carbonic Anhydrase IX in Cancer[J].Journal of Medical Information,2018,31(21):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(21):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]白 雪,邓 琦.血液系统肿瘤的细胞治疗研究进展[J].医学信息,2018,31(10):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
　BAI Xue,DENG Qi.Advances in Cell Therapy for Blood System Tumor[J].Journal of Medical Information,2018,31(21):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
[5]李 轩,王子为,赵靖萱,等.肿瘤预后预测领域机器学习应用的文献计量与热点可视化分析[J].医学信息,2022,35(09):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
　LI Xuan,WANG Zi-wei,ZHAO Jing-xuan,et al.Visualization Analysis on Bibliometrics and Hot Spots of Machine Learning Applications in the Field of Tumor Prognosis Prediction[J].Journal of Medical Information,2022,35(21):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
[6]王 静,刘 梅,焦菊凤.知-信-行健康教育模式对PICC置管肿瘤 患者自我护理能力的影响[J].医学信息,2018,31(11):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
　WANG Jing,LIU Mei,JIAO Ju-feng.Effect of Knowledge-belief-behavioral Health Education Model on the Self-care Ability of Patients with Cancer in PICC Catheterization[J].Journal of Medical Information,2018,31(21):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
[7]史红娟,李群锋,赵 华,等.舒林酸抗肿瘤作用的研究进展[J].医学信息,2018,31(12):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
　SHI Hong-juan,LI Qun-feng,ZHAO Hua,et al.Advances in Research on Anti-tumor Effect of Sulindac[J].Journal of Medical Information,2018,31(21):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
[8]庞小坤,韩 梅,江心灿,等.当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析[J].医学信息,2019,32(02):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
　Pang Xiao-kun,Han Mei,Jiang Xin-can,et al.Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy[J].Journal of Medical Information,2019,32(21):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
[9]张 慧,胡广越,殷 红.菌群干预与免疫治疗的研究进展[J].医学信息,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
　ZHAHG Hui,HU Guang-yue,YIN Hong.Research Progress in Microbial Intervention and Immunotherapy[J].Journal of Medical Information,2022,35(21):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
[10]郑文灿,法艳梅,吕亚青,等.苦参碱抗肿瘤机制的分子生物学研究进展[J].医学信息,2018,31(19):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
　ZHENG Wen-can,FA Yan-mei,LV Ya-qing,et al.Advances in Molecular Biology of Matrine Antitumor Mechanism[J].Journal of Medical Information,2018,31(21):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]

更新日期/Last Update: 1900-01-01